Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) CEO Pascal Touchon sold 14,291 shares of the stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $1.66, for a total value of $23,723.06. Following the completion of the transaction, the chief executive officer now directly owns 706,671 shares in […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) has received a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) CEO Pascal Touchon sold 14,291 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $1.66, for a total value of $23,723.06. Following the transaction, the chief executive officer now owns 706,671 shares of the […]
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) have been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the […]
HC Wainwright reiterated their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report published on Wednesday, The Fly reports. HC Wainwright currently has a $28.00 price target on the biotechnology company’s stock, up from their previous price target of $27.00. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2023 […]